OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes

被引:63
作者
Field, LL
Bonnevie-Nielsen, V
Pociot, F
Lu, S
Nielsen, TB
Beck-Nielsen, H
机构
[1] Univ British Columbia, Dept Med Genet, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada
[3] Steno Diabet Ctr, DK-2820 Gentofte, Denmark
[4] Odense Univ, Dept Endocrinol, Odense, Denmark
关键词
D O I
10.2337/diabetes.54.5.1588
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both genetic and nongenetic factors contribute to the development of type 1 diabetes. Many investigations, including prospective studies of high-risk children, have implicated virus infections as predisposing environmental agents. We previously reported that basal activity of the key antiviral enzyme 2'5'-oligoadenylate synthetase (2'5'AS) was significantly elevated in type I diabetic patients compared with healthy control subjects. Recently, we showed that an A/G splice site single nucleotide polymorphism (SNP) in the OAS1] gene encoding 2'5'AS is strongly associated with basal 2'5'AS activity. Basal enzyme activity was highest in individuals with GG genotype and lowest in those with AA genotype. In the present study, we genotyped 835 type I diabetic and 401 healthy siblings at the OAS1] splice site polymorphism and (for comparison) at an A/C SNP of the insulin (IDDM2) locus. Results showed that OAS1 GG and GA were significantly increased in diabetic compared with healthy siblings (P = 0.0023). The strength of association was similar to that at IDDM2, where, as expected, the C/C (variable number tandem repeat class I homozygote) genotype was increased in affected compared with healthy siblings (P = 0.0025). The results suggest that host genetic response to virus infection could influence susceptibility to type I diabetes.
引用
收藏
页码:1588 / 1591
页数:4
相关论文
共 22 条
[1]   Variation in antiviral 2′,5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene [J].
Bonnevie-Nielsen, V ;
Field, LL ;
Lu, S ;
Zheng, DJ ;
Li, M ;
Martensen, PM ;
Nielsen, TB ;
Beck-Nielsen, H ;
Lau, YL ;
Pociot, F .
AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (04) :623-633
[2]   The antiviral 2′,5′-oligoadenylate synthetase is persistently activated in type 1 diabetes [J].
Bonnevie-Nielsen, V ;
Martensen, PM ;
Justesen, J ;
Kyvik, KO ;
Kristensen, B ;
Levin, K ;
Beck-Nielsen, H ;
Worsaa, A ;
Dyrberg, T .
CLINICAL IMMUNOLOGY, 2000, 96 (01) :11-18
[3]   ASSOCIATION OF IDDM AND ATTENUATED RESPONSE OF 2',5'-OLIGOADENYLATE SYNTHETASE TO YELLOW-FEVER VACCINE [J].
BONNEVIENIELSEN, V ;
LARSEN, ML ;
FRIFELT, JJ ;
MICHELSEN, B ;
LERNMARK, A .
DIABETES, 1989, 38 (12) :1636-1642
[4]   Genetic linkage and association studies of Type I diabetes: challenges and rewards [J].
Field, LL .
DIABETOLOGIA, 2002, 45 (01) :21-35
[5]   A specific isozyme of 2′-5′ oligoadenylate synthetase is a dual function proapoptotic protein of the Bcl-2 family [J].
Ghosh, A ;
Sarkar, SN ;
Rowe, TM ;
Sen, GC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (27) :25447-25455
[6]   Islet cell antibody seroconversion in children is temporally associated with enterovirus infections [J].
Hiltunen, M ;
Hyoty, H ;
Knip, M ;
Ilonen, J ;
Reijonen, H ;
Vahasalo, P ;
Roivainen, M ;
Lonnrot, M ;
Leinikki, P ;
Hovi, T ;
Akerblom, HK ;
Tuomilehto, J ;
Lounamaa, R ;
Toivanen, L ;
Virtala, E ;
Pitkaniemi, J ;
Fagerlund, A ;
Flittner, M ;
Gustafsson, B ;
Haggqvist, C ;
Hakulinen, A ;
Herva, L ;
Hiltunen, P ;
Huhtamaki, T ;
Huttunen, NP ;
Huupponen, T ;
Hyttinen, M ;
Joki, T ;
Jokisalo, R ;
Kaar, ML ;
Kallio, S ;
Kaprio, EA ;
Kaski, U ;
Knip, M ;
Laine, L ;
Lappalainen, J ;
Maenpaa, J ;
Makela, AL ;
Niemi, K ;
Niiranen, A ;
Nuuja, A ;
Ojajarvi, P ;
Otonkoski, T ;
Pihlajamaki, K ;
Pontynen, S ;
Rajantie, J ;
Sankala, J ;
Schumacher, J ;
Sillanpaa, M ;
Stahlberg, MR .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (03) :554-560
[7]   A PROSPECTIVE-STUDY OF THE ROLE OF COXSACKIE-B AND OTHER ENTEROVIRUS INFECTIONS IN THE PATHOGENESIS OF IDDM [J].
HYOTY, H ;
HILTUNEN, M ;
KNIP, M ;
LAAKKONEN, M ;
VAHASALO, P ;
KARJALAINEN, J ;
KOSKELA, P ;
ROIVAINEN, M ;
LEINIKKI, P ;
HOVI, T ;
AKERBLOM, HK ;
TUOMILEHTO, J ;
LOUNAMAA, R ;
TOIVANEN, L ;
VIRTALA, E ;
PITKANIEMI, J ;
FAGERLUND, A ;
FLITTNER, M ;
GUSTAFFSON, B ;
HAGGQVIST, C ;
HAKULINEN, A ;
HERVA, L ;
HILTUNEN, P ;
HUHTAMAKI, T ;
HUTTUNEN, NP ;
HUUPPONEN, T ;
HYTTINEN, M ;
JOKI, T ;
JOKISALO, R ;
KAAR, ML ;
KALLIO, S ;
KAPRIO, EA ;
KASKI, U ;
LAINE, L ;
LAPPALAINEN, J ;
MAENPAA, J ;
MAKELA, AL ;
NIEMI, K ;
NIIRANEN, A ;
NUUJA, A ;
OJAJARVI, P ;
OTONKOSKI, T ;
PIHLAJAMAKI, K ;
PONTYNEN, S ;
RAJANTIE, J ;
SANKALA, J ;
SCHUMACHER, J ;
SILLANPAA, M ;
STAHLBERG, MR ;
STRAHLMANN, CH .
DIABETES, 1995, 44 (06) :652-657
[8]   T cell responses to enterovirus antigens and to β-cell autoantigens in unaffected children positive for IDDM-associated autoantibodies [J].
Juhela, S ;
Hyöty, H ;
Hinkkanen, A ;
Elliott, J ;
Roivainen, M ;
Kulmala, P ;
Rahko, J ;
Knip, M ;
Ilonen, J .
JOURNAL OF AUTOIMMUNITY, 1999, 12 (04) :269-278
[9]  
JULIER C, 1994, AM J HUM GENET, V55, P1247
[10]   Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR [J].
Knapp, S ;
Yee, LJ ;
Frodsham, AJ ;
Hennig, BJW ;
Hellier, S ;
Zhang, L ;
Wright, M ;
Chiaramonte, M ;
Graves, M ;
Thomas, HC ;
Hill, AVS ;
Thursz, MR .
GENES AND IMMUNITY, 2003, 4 (06) :411-419